Jordan Nava

Nov 22, 2023 | jamanetwork.com | Stephanie Le |Samantha Herbert |Reneé Haughton |Jordan Nava

Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid Bullous pemphigoid (BP) is a rare immunobullous disease with no US Food & Drug Administration-approved treatment. Rituximab (RTX) for BP has yielded mixed results, possibly because of an inability to substantially alter serum IgE levels.1 In contrast, omalizumab (OMZ) is faster acting and targets IgE but with mixed effectiveness.2 However, these drugs may work synergistically.